1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Ascletis Becomes Another Contender For ‘Best-In-Class’ Oral GLP-1

 
• By Andrew McConaghie

ASC30's Phase I study has produced the best-yet weight loss achieved by an oral drug at 28 days, and it could be a serious rival for Lilly’s frontrunner orforglipron.

Jeans with a tape measure as a belt
Survodutide Achieved Up To 18.7% Weight Loss At 46 Weeks • Source: Shutterstock

Ascletis Pharma only joined the obesity field last September but has just presented early data for what could be a best-in-class oral GLP-1 agonist.

Data from the Phase Ib MAD study show the Hong Kong-based company’s ASC30 oral once-daily candidate produced mean body weight reductions from baseline of 4.3% and 6

Key Takeaways
  • Ascletis is developing ASC30 as the first small-molecule GLP-1 therapy to be taken once-a month subcutaneously and once-daily orally
  • The new oral Phase I data puts

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

More from Therapy Areas

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.